elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Institutions
beta
Research Intelligence
Lab
API & MCP
Pricing
Log in
Sign up
Home
/
Subjects
/
Cabozantinib
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Cabozantinib
RIS
0.001
(Research Intensity Score)
Papers
102
Top papers
Thyroid Cancer
2024 · 638 citations
Targeted therapy for hepatocellular carcinoma
2020 · 785 citations
Molecular Biology of Osteosarcoma
2020 · 348 citations
Pheochromocytoma: an updated scoping review from clinical presentation to management and treatment
2024 · 41 citations
Medication-induced osteonecrosis of the jaw: a review of cases from the Food and Drug Administration Adverse Event Reporting System (FAERS)
2023 · 63 citations
Newest papers
Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Renal Cell Carcinoma With Bone Metastases: RADICAL (Alliance A031801)
2026 · 1 citations
A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).
2026 · 1 citations
Redefining the Role of Chemotherapy and Targeted Cytotoxic Delivery in Lung Neuroendocrine Tumors
2026
Targeted Therapies in Endocrine Malignancies
2026
Antineoplastic and Immunomodulatory Effects of Cabozantinib in Continuous and Primary Human Anaplastic Thyroid Cancer Cells
2026
A sample from the 100 top papers behind Cabozantinib.
Create a free account to browse them all →
Cabozantinib's history
Research intensity over time
Explore Cabozantinib's full history
Hover any year for its value and switch resolutions with a free account. Personal adds monthly detail and the historical-intensity (HRI) line.
Create a free account
Already have an account?
Log in
to explore the data.
Close ✕
Cabozantinib's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link